Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LNZ100 · 1 trial · 1 indication
Maximum plasma concentrations of LNZ100 and LNZ101
Time of maximum plasma concentrations of LNZ100 and LNZ101
Area under the concentration-time curve from time 0 to time t of LNZ100 and LNZ100
Area under the concentration-time curve from time 0 to infinity of LNZ100 and LNZ101
Terminal half-life of LNZ100 and LNZ101
The number of patients who experience one or more AE during the treatment period
| Arm | Type | Description |
|---|---|---|
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | EXPERIMENTAL | Drug: Aceclidine/Brimonidine ophthalmic solution Other Names: LNZ101 |
| LNZ100 (Aceclidine) ophthalmic solution | EXPERIMENTAL | Drug: Aceclidine ophthalmic solution Other Names: LNZ100 |
| Placebo (Vehicle) ophthalmic solution | PLACEBO_COMPARATOR | Drug: Placebo (Vehicle) ophthalmic solution Other Names: NA |
| Name | Type | Description |
|---|---|---|
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | DRUG | Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later |
| LNZ100 (Aceclidine) ophthalmic solution | DRUG | Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later |
| Placebo (Vehicle) ophthalmic solution | DRUG | Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later |
Inclusion Criteria 1. Be able and willing to provide written informed consent prior to any study procedure being performed. 2. Be able to and willing to use investigational products per study requirements and attend all study assessments, including admission to and stay in the CRU on required study...
LNZ100 is an investigational small molecule being developed for presbyopia, an age-related eye condition that reduces the eye's ability to focus on close objects. It is formulated as an ophthalmic solution, meaning it is applied directly to the eye. The drug is currently in clinical development and has not been approved by regulatory authorities.
LNZ100 is being developed by Milestone Pharmaceuticals Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol MIST. The company is conducting clinical trials to evaluate the safety and tolerability of the drug in patients with presbyopia.
LNZ100 is in Phase 1 clinical development. A Phase 1 trial has been completed, which focused on evaluating the safety, tolerability, and pharmacokinetics of the drug. The drug is still investigational and has not received approval from regulatory agencies for commercial use.
LNZ100 has been studied in one completed Phase 1 clinical trial, identified as NCT06270030. This trial enrolled 21 healthy adult participants in China and assessed the safety, tolerability, and pharmacokinetics of LNZ100 ophthalmic solutions in individuals with presbyopia.
LNZ100 and LNZ101 are distinct investigational drugs, though they were both evaluated in the same clinical trial, NCT06270030. That trial assessed the safety, tolerability, and pharmacokinetics of both LNZ101 and LNZ100 ophthalmic solutions in healthy adults with presbyopia. They are separate formulations being developed by the same company.